Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Primary Purpose
Venous Thrombosis
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Enoxaparin
warfarin
Placebo for apixaban
Placebo for enoxaparin
Placebo for warfarin
apixaban
Sponsored by
About this trial
This is an interventional treatment trial for Venous Thrombosis
Eligibility Criteria
Inclusion Criteria:
- Men and women ≥ 18 years of age
- Clinical diagnosis of DVT or PE
Exclusion Criteria:
- Contraindications for enoxaparin or warfarin
- Active bleeding or high risk for serious bleeding
- Short life expectancy
- Uncontrolled high blood pressure
- Significantly impaired kidney or liver function
Sites / Locations
- Alabama Clinical Therapeutics, Llc
- Horizon Research Group, Inc.
- Fort Smith Lung Center
- University Of Arkansas For Medical Sciences
- Beaver Medical Group
- University Of California San Francisco-Fresno
- University Of California, Davis Medical Center
- Chest Medicine & Critical Care Medical Gr. Inc.
- Stanford University Medical Center
- Harbor Ucla Medical Center
- New West Physicians
- Drogue Medical, Llc
- Bridgeport Hospital
- Dept Of Internal Med, Sect Of Pulmonary & Critical Care Med
- George Washington University Medical Faculty Associates
- Bay Pines Va Healthcare Systems
- Daniel G. Lorch, Jr, Md, Cpi
- Research Alliance, Inc.
- River City Clinical Research
- Pasadena Center For Medical Research
- Tampa Clinical Research
- Office Of Michele S. Maholtz Md
- Cleveland Clinic Florida
- Atlanta Pulmonary Group
- Atlanta Institute For Medical Research, Inc
- Chatham Hospitalists
- Gateway Cardiology. P.C
- West Suburban Medical Center
- Infectious Disease Of Indiana Psc
- Heartland Vascular Medicine And Surgery
- Kentucky Lung Clinic
- Univ. Of Kentucky Dept. Of Surgery
- Research Integrity, Llc
- Pen Bay Medical Center
- Anne Arundel Medical Center
- R Adams Cowley Shock Trauma Center
- Medstar Research Health Institute
- Henry Ford Hospital
- Hurley Medical Center
- Mississippi Medical Research, Llc
- University Of Missouri-Columbia
- Veterans Affairs Medical Center
- Washington University School Of Medicine
- St. John'S Mercy Medical Center
- Mercury Street Medical Group, Pllc
- Great Falls Clinic, Llp
- Internal Medical Associates Of Grand Island, P.C
- Creighton University Medical Center
- Morristown Memorial Hospital
- Pulmonary & Critical Care Services, Pc
- Kaleida Health System
- Richmond University Medical Center
- New York Medical College
- Carolinas Medical Center
- Duke University Medical Center
- Rex Healthcare
- Piedmont Healthcare/Research
- Wilmington Medical Research
- Clinical Trials Of America, Inc.
- Altru Health System Clinic
- Huron Hospital
- Remington Davis Inc.
- Oregon Health Science University
- Penn State Milton S. Hershey Medical Center
- Greenville Hospital System
- Palmetto Clinical Research
- Holston Medical Group
- Kore Cv Research
- Primecare Medical Group
- Cancer Care Centers Of South Texas
- University Of Utah Medical Center
- Lake Washington Vascular, Pllc
- Franciscan Research Center
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Apixaban
Enoxaparin + Warfarin
Arm Description
apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.
Outcomes
Primary Outcome Measures
Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment
VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat).
Secondary Outcome Measures
Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded.
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite.
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding
VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT).
Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period
DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).
Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period
PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).
Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).
Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).
Incidence of All-Cause Death During the Intended Treatment Period
Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information).
Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants
All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants
Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug).
Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants
Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants
Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants
Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants
Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: < 0.75*LLN, > 1.25*ULN; Hemoglobin: <= 11.5 g/dL (males), <= 9.5 g/dL (females); Hematocrit: <= 37% (males), <= 32% (females); Erythrocytes: <0.75*10^6 c/µL*PreRx; Platelet count: < 75*10^9 c/L, > 700*10^9 c/L; ANC: < 1.00*10^3 c/µL; Abs eosinophils: > 0.750*10^3 c/µL; Abs Basophils: > 400/MM^3; Abs Monocytes> 2000/MM^3; Abs Lymphocytes: < 0.750*10*3 c/ µL, > 7.5*10^3 c/ µL.
Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*pre-dose or > ULN if pre-dose > ULN then use > 1.05*pre-dose or < LLN.
Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN.
Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests
Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if pre-dose < LLN then use 0.9* pre-dose or > ULN if pre-dose > ULN then use 1.1 *pre-dose or <LLN; Uric acid High: > 1.5* ULN, or if pre-dose > ULN then use > 2 *pre-dose.
Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests
All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4.
Full Information
NCT ID
NCT00643201
First Posted
March 20, 2008
Last Updated
April 17, 2014
Sponsor
Bristol-Myers Squibb
Collaborators
Pfizer
1. Study Identification
Unique Protocol Identification Number
NCT00643201
Brief Title
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Official Title
A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism
Study Type
Interventional
2. Study Status
Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
July 2008 (undefined)
Primary Completion Date
March 2013 (Actual)
Study Completion Date
March 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb
Collaborators
Pfizer
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Thrombosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
5614 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Apixaban
Arm Type
Active Comparator
Arm Description
apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
Arm Title
Enoxaparin + Warfarin
Arm Type
Experimental
Arm Description
Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.
Intervention Type
Drug
Intervention Name(s)
Enoxaparin
Intervention Description
solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
Intervention Type
Drug
Intervention Name(s)
warfarin
Other Intervention Name(s)
Coumadin, BMS-565793
Intervention Description
tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Intervention Type
Drug
Intervention Name(s)
Placebo for apixaban
Intervention Description
tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
Intervention Type
Drug
Intervention Name(s)
Placebo for enoxaparin
Intervention Description
solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
Intervention Type
Drug
Intervention Name(s)
Placebo for warfarin
Intervention Description
tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
Intervention Type
Drug
Intervention Name(s)
apixaban
Other Intervention Name(s)
BMS-562247
Intervention Description
tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Primary Outcome Measure Information:
Title
Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment
Description
VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat).
Time Frame
Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)
Secondary Outcome Measure Information:
Title
Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death
Description
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded.
Time Frame
Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death
Description
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite.
Time Frame
Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding
Description
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle
Time Frame
Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding
Description
VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT).
Time Frame
Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period
Description
DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).
Time Frame
Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period
Description
PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).
Time Frame
Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period
Description
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period
Description
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of All-Cause Death During the Intended Treatment Period
Description
Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information).
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants
Description
All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants
Description
Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug).
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants
Description
Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants
Description
Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants
Description
Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants
Description
Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time Frame
First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued
Title
Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests
Description
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: < 0.75*LLN, > 1.25*ULN; Hemoglobin: <= 11.5 g/dL (males), <= 9.5 g/dL (females); Hematocrit: <= 37% (males), <= 32% (females); Erythrocytes: <0.75*10^6 c/µL*PreRx; Platelet count: < 75*10^9 c/L, > 700*10^9 c/L; ANC: < 1.00*10^3 c/µL; Abs eosinophils: > 0.750*10^3 c/µL; Abs Basophils: > 400/MM^3; Abs Monocytes> 2000/MM^3; Abs Lymphocytes: < 0.750*10*3 c/ µL, > 7.5*10^3 c/ µL.
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests
Description
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*pre-dose or > ULN if pre-dose > ULN then use > 1.05*pre-dose or < LLN.
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests
Description
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN.
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests
Description
Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if pre-dose < LLN then use 0.9* pre-dose or > ULN if pre-dose > ULN then use 1.1 *pre-dose or <LLN; Uric acid High: > 1.5* ULN, or if pre-dose > ULN then use > 2 *pre-dose.
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Title
Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests
Description
All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4.
Time Frame
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women ≥ 18 years of age
Clinical diagnosis of DVT or PE
Exclusion Criteria:
Contraindications for enoxaparin or warfarin
Active bleeding or high risk for serious bleeding
Short life expectancy
Uncontrolled high blood pressure
Significantly impaired kidney or liver function
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Alabama Clinical Therapeutics, Llc
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35235
Country
United States
Facility Name
Horizon Research Group, Inc.
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36608
Country
United States
Facility Name
Fort Smith Lung Center
City
Fort Smith
State/Province
Arkansas
ZIP/Postal Code
72901
Country
United States
Facility Name
University Of Arkansas For Medical Sciences
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
Beaver Medical Group
City
Banning
State/Province
California
ZIP/Postal Code
92220
Country
United States
Facility Name
University Of California San Francisco-Fresno
City
Fresno
State/Province
California
ZIP/Postal Code
93701
Country
United States
Facility Name
University Of California, Davis Medical Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Facility Name
Chest Medicine & Critical Care Medical Gr. Inc.
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Stanford University Medical Center
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Name
Harbor Ucla Medical Center
City
Torrance
State/Province
California
ZIP/Postal Code
90509
Country
United States
Facility Name
New West Physicians
City
Golden
State/Province
Colorado
ZIP/Postal Code
80401
Country
United States
Facility Name
Drogue Medical, Llc
City
Wheat Ridge
State/Province
Colorado
ZIP/Postal Code
80033
Country
United States
Facility Name
Bridgeport Hospital
City
Bridgeport
State/Province
Connecticut
ZIP/Postal Code
06610
Country
United States
Facility Name
Dept Of Internal Med, Sect Of Pulmonary & Critical Care Med
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Facility Name
George Washington University Medical Faculty Associates
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20037
Country
United States
Facility Name
Bay Pines Va Healthcare Systems
City
Bay Pines
State/Province
Florida
ZIP/Postal Code
33744
Country
United States
Facility Name
Daniel G. Lorch, Jr, Md, Cpi
City
Brandon
State/Province
Florida
ZIP/Postal Code
33511
Country
United States
Facility Name
Research Alliance, Inc.
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33756
Country
United States
Facility Name
River City Clinical Research
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
Pasadena Center For Medical Research
City
St. Petersburg
State/Province
Florida
ZIP/Postal Code
33707
Country
United States
Facility Name
Tampa Clinical Research
City
Tampa
State/Province
Florida
ZIP/Postal Code
33624
Country
United States
Facility Name
Office Of Michele S. Maholtz Md
City
Vero Beach
State/Province
Florida
ZIP/Postal Code
32960
Country
United States
Facility Name
Cleveland Clinic Florida
City
Weston
State/Province
Florida
ZIP/Postal Code
33331
Country
United States
Facility Name
Atlanta Pulmonary Group
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Atlanta Institute For Medical Research, Inc
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30030
Country
United States
Facility Name
Chatham Hospitalists
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31405
Country
United States
Facility Name
Gateway Cardiology. P.C
City
Jerseyville
State/Province
Illinois
ZIP/Postal Code
62052
Country
United States
Facility Name
West Suburban Medical Center
City
Oak Park
State/Province
Illinois
ZIP/Postal Code
60302
Country
United States
Facility Name
Infectious Disease Of Indiana Psc
City
Carmel
State/Province
Indiana
ZIP/Postal Code
46032
Country
United States
Facility Name
Heartland Vascular Medicine And Surgery
City
Windsor Heights
State/Province
Iowa
ZIP/Postal Code
50324
Country
United States
Facility Name
Kentucky Lung Clinic
City
Hazard
State/Province
Kentucky
ZIP/Postal Code
41701
Country
United States
Facility Name
Univ. Of Kentucky Dept. Of Surgery
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States
Facility Name
Research Integrity, Llc
City
Owensboro
State/Province
Kentucky
ZIP/Postal Code
42303
Country
United States
Facility Name
Pen Bay Medical Center
City
Rockport
State/Province
Maine
ZIP/Postal Code
04856
Country
United States
Facility Name
Anne Arundel Medical Center
City
Annapolis
State/Province
Maryland
ZIP/Postal Code
21401
Country
United States
Facility Name
R Adams Cowley Shock Trauma Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
Medstar Research Health Institute
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21237
Country
United States
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Hurley Medical Center
City
Flint
State/Province
Michigan
ZIP/Postal Code
48503
Country
United States
Facility Name
Mississippi Medical Research, Llc
City
Picayune
State/Province
Mississippi
ZIP/Postal Code
39466
Country
United States
Facility Name
University Of Missouri-Columbia
City
Columbia
State/Province
Missouri
ZIP/Postal Code
65212
Country
United States
Facility Name
Veterans Affairs Medical Center
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64128
Country
United States
Facility Name
Washington University School Of Medicine
City
St Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
St. John'S Mercy Medical Center
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Mercury Street Medical Group, Pllc
City
Butte
State/Province
Montana
ZIP/Postal Code
59701
Country
United States
Facility Name
Great Falls Clinic, Llp
City
Great Falls
State/Province
Montana
ZIP/Postal Code
59405
Country
United States
Facility Name
Internal Medical Associates Of Grand Island, P.C
City
Grand Island
State/Province
Nebraska
ZIP/Postal Code
68803
Country
United States
Facility Name
Creighton University Medical Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68131
Country
United States
Facility Name
Morristown Memorial Hospital
City
Morristown
State/Province
New Jersey
ZIP/Postal Code
07962
Country
United States
Facility Name
Pulmonary & Critical Care Services, Pc
City
Albany
State/Province
New York
ZIP/Postal Code
12205
Country
United States
Facility Name
Kaleida Health System
City
Buffalo
State/Province
New York
ZIP/Postal Code
14209
Country
United States
Facility Name
Richmond University Medical Center
City
Staten Island
State/Province
New York
ZIP/Postal Code
10310
Country
United States
Facility Name
New York Medical College
City
Valhalla
State/Province
New York
ZIP/Postal Code
10595
Country
United States
Facility Name
Carolinas Medical Center
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28203
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Rex Healthcare
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
Piedmont Healthcare/Research
City
Statesville
State/Province
North Carolina
ZIP/Postal Code
28625
Country
United States
Facility Name
Wilmington Medical Research
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Clinical Trials Of America, Inc.
City
Winston Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Altru Health System Clinic
City
Grand Forks
State/Province
North Dakota
ZIP/Postal Code
58201
Country
United States
Facility Name
Huron Hospital
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44112
Country
United States
Facility Name
Remington Davis Inc.
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43215
Country
United States
Facility Name
Oregon Health Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Penn State Milton S. Hershey Medical Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Facility Name
Greenville Hospital System
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
Facility Name
Palmetto Clinical Research
City
Summerville
State/Province
South Carolina
ZIP/Postal Code
29485
Country
United States
Facility Name
Holston Medical Group
City
Bristol
State/Province
Tennessee
ZIP/Postal Code
37620
Country
United States
Facility Name
Kore Cv Research
City
Jackson
State/Province
Tennessee
ZIP/Postal Code
38305
Country
United States
Facility Name
Primecare Medical Group
City
Houston
State/Province
Texas
ZIP/Postal Code
77024
Country
United States
Facility Name
Cancer Care Centers Of South Texas
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
University Of Utah Medical Center
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84132
Country
United States
Facility Name
Lake Washington Vascular, Pllc
City
Bellevue
State/Province
Washington
ZIP/Postal Code
98004
Country
United States
Facility Name
Franciscan Research Center
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
Local Institution
City
Ciudad Autonoma De Buenos Aire
State/Province
Buenos Aires
ZIP/Postal Code
C1180AAX
Country
Argentina
Facility Name
Local Institution
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
2000
Country
Argentina
Facility Name
Local Institution
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000CVB
Country
Argentina
Facility Name
Local Institution
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000DSV
Country
Argentina
Facility Name
Local Institution
City
Buenos Aires
ZIP/Postal Code
C1280AEB
Country
Argentina
Facility Name
Local Institution
City
Cordoba
ZIP/Postal Code
5000
Country
Argentina
Facility Name
Local Institution
City
Corrientes
ZIP/Postal Code
3400
Country
Argentina
Facility Name
Local Institution
City
Garran
State/Province
Australian Capital Territory
ZIP/Postal Code
2605
Country
Australia
Facility Name
Local Institution
City
Concord
State/Province
New South Wales
ZIP/Postal Code
2139
Country
Australia
Facility Name
Local Institution
City
Kogarah
State/Province
New South Wales
ZIP/Postal Code
2217
Country
Australia
Facility Name
Local Institution
City
Lismore
State/Province
New South Wales
ZIP/Postal Code
2480
Country
Australia
Facility Name
Local Institution
City
Randwick
State/Province
New South Wales
ZIP/Postal Code
2031
Country
Australia
Facility Name
Local Institution
City
Herston
State/Province
Queensland
ZIP/Postal Code
4029
Country
Australia
Facility Name
Local Institution
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
Local Institution
City
Bedford Park
State/Province
South Australia
ZIP/Postal Code
5042
Country
Australia
Facility Name
Local Institution
City
Hobart
State/Province
Tasmania
ZIP/Postal Code
7000
Country
Australia
Facility Name
Local Institution
City
Box Hill
State/Province
Victoria
ZIP/Postal Code
3128
Country
Australia
Facility Name
Local Institution
City
Clayton
State/Province
Victoria
ZIP/Postal Code
3168
Country
Australia
Facility Name
Local Institution
City
Ringwood East
State/Province
Victoria
ZIP/Postal Code
3135
Country
Australia
Facility Name
Local Institution
City
Windsor
State/Province
Victoria
ZIP/Postal Code
3181
Country
Australia
Facility Name
Local Institution
City
Perth
State/Province
Western Australia
ZIP/Postal Code
6001
Country
Australia
Facility Name
Local Institution
City
Graz
ZIP/Postal Code
8036
Country
Austria
Facility Name
Local Institution
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Facility Name
Local Institution
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
Local Institution
City
Vienna
ZIP/Postal Code
1100
Country
Austria
Facility Name
Local Institution
City
Vienna
ZIP/Postal Code
1140
Country
Austria
Facility Name
Local Institution
City
Vienna
ZIP/Postal Code
1160
Country
Austria
Facility Name
Local Institution
City
Wien
ZIP/Postal Code
1090
Country
Austria
Facility Name
Local Institution
City
Belo Horizonte - Mg
State/Province
Minas Gerais
ZIP/Postal Code
30150
Country
Brazil
Facility Name
Local Institution
City
Curitiba
State/Province
Parana
ZIP/Postal Code
80035
Country
Brazil
Facility Name
Local Institution
City
Curitiba
State/Province
Parana
ZIP/Postal Code
80050
Country
Brazil
Facility Name
Local Institution
City
Curitiba
State/Province
Parana
ZIP/Postal Code
80810
Country
Brazil
Facility Name
Local Institution
City
Curitiba
State/Province
Parana
ZIP/Postal Code
81520
Country
Brazil
Facility Name
Local Institution
City
Rio Janeiro
State/Province
Rio De Janeiro
ZIP/Postal Code
22280
Country
Brazil
Facility Name
Local Institution
City
Port Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90020
Country
Brazil
Facility Name
Local Institution
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90035
Country
Brazil
Facility Name
Local Institution
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90110
Country
Brazil
Facility Name
Local Institution
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90610
Country
Brazil
Facility Name
Local Institution
City
Botucatu
State/Province
Sao Paulo
ZIP/Postal Code
18618
Country
Brazil
Facility Name
Local Institution
City
Liberdade
State/Province
Sao Paulo
ZIP/Postal Code
01509
Country
Brazil
Facility Name
Local Institution
City
Sao Jose Do Rio Preto
State/Province
Sao Paulo
ZIP/Postal Code
15090
Country
Brazil
Facility Name
Local Institution
City
Sao Bernardo do Campo
State/Province
SP
ZIP/Postal Code
09715
Country
Brazil
Facility Name
Local Institution
City
Rio De Janeiro
ZIP/Postal Code
20551
Country
Brazil
Facility Name
Local Institution
City
Sao Paulo
ZIP/Postal Code
01323
Country
Brazil
Facility Name
Local Institution
City
Sao Paulo
ZIP/Postal Code
04005
Country
Brazil
Facility Name
Local Institution
City
Sao Paulo
ZIP/Postal Code
04025
Country
Brazil
Facility Name
Local Institution
City
Sao Paulo
ZIP/Postal Code
05403
Country
Brazil
Facility Name
Local Institution
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T5H 4B9
Country
Canada
Facility Name
Local Institution
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2B7
Country
Canada
Facility Name
Local Institution
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 1M9
Country
Canada
Facility Name
Local Institution
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6Z 1Y6
Country
Canada
Facility Name
Local Institution
City
Victoria
State/Province
British Columbia
ZIP/Postal Code
V8R 6R5
Country
Canada
Facility Name
Local Institution
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R2H 2A6
Country
Canada
Facility Name
Local Institution
City
Saint John
State/Province
New Brunswick
ZIP/Postal Code
E2L 4L2
Country
Canada
Facility Name
Local Institution
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8L 2X2
Country
Canada
Facility Name
Local Institution
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 4A6
Country
Canada
Facility Name
Local Institution
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8S 4K1
Country
Canada
Facility Name
Local Institution
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y 4E9
Country
Canada
Facility Name
Local Institution
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2C4
Country
Canada
Facility Name
Local Institution
City
Waterloo
State/Province
Ontario
ZIP/Postal Code
N2J 1C4
Country
Canada
Facility Name
Local Institution
City
Windsor
State/Province
Ontario
ZIP/Postal Code
N8X 5A6
Country
Canada
Facility Name
Local Institution
City
Greenfield Park
State/Province
Quebec
ZIP/Postal Code
J4V 2H1
Country
Canada
Facility Name
Local Institution
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1T 2M4
Country
Canada
Facility Name
Local Institution
City
St. Jerome
State/Province
Quebec
ZIP/Postal Code
J7Z 5T3
Country
Canada
Facility Name
Local Institution
City
Punta Arenas
State/Province
Magallanes Antartica
ZIP/Postal Code
6212296
Country
Chile
Facility Name
Local Institution
City
Independencia
State/Province
Metropolitana
ZIP/Postal Code
XXXXX
Country
Chile
Facility Name
Local Institution
City
Santiago
State/Province
Metropolitana
ZIP/Postal Code
7600448
Country
Chile
Facility Name
Local Institution
City
Santiago
State/Province
Metropolitana
ZIP/Postal Code
8330024
Country
Chile
Facility Name
Local Institution
City
Vina Del Mar
State/Province
Valparaiso
ZIP/Postal Code
2520000
Country
Chile
Facility Name
Local Institution
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100020
Country
China
Facility Name
Local Institution
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100029
Country
China
Facility Name
Local Institution
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100032
Country
China
Facility Name
Local Institution
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100035
Country
China
Facility Name
Local Institution
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100037
Country
China
Facility Name
Local Institution
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100038
Country
China
Facility Name
Local Institution
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100053
Country
China
Facility Name
Local Institution
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100191
Country
China
Facility Name
Local Institution
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510080
Country
China
Facility Name
Local Institution
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China
Facility Name
Local Institution
City
Shengyang
State/Province
Liaoning
ZIP/Postal Code
110004
Country
China
Facility Name
Local Institution
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
Facility Name
Local Institution
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200127
Country
China
Facility Name
Local Institution
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
130016
Country
China
Facility Name
Local Institution
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310016
Country
China
Facility Name
Local Institution
City
Xian
ZIP/Postal Code
710032
Country
China
Facility Name
Local Institution
City
Hradec Kralove
ZIP/Postal Code
500 05
Country
Czech Republic
Facility Name
Local Institution
City
Kladno
ZIP/Postal Code
272 59
Country
Czech Republic
Facility Name
Local Institution
City
Litomysl
ZIP/Postal Code
570 14
Country
Czech Republic
Facility Name
Local Institution
City
Mestec Kralove
ZIP/Postal Code
289 03
Country
Czech Republic
Facility Name
Local Institution
City
Ostrava Vitkovice
ZIP/Postal Code
703 84
Country
Czech Republic
Facility Name
Local Institution
City
Ostrava
ZIP/Postal Code
708 52
Country
Czech Republic
Facility Name
Local Institution
City
Praha 10
ZIP/Postal Code
100 34
Country
Czech Republic
Facility Name
Local Institution
City
Praha 1
ZIP/Postal Code
110 00
Country
Czech Republic
Facility Name
Local Institution
City
Praha 1
ZIP/Postal Code
118 33
Country
Czech Republic
Facility Name
Local Institution
City
Praha 2
ZIP/Postal Code
128 08
Country
Czech Republic
Facility Name
Local Institution
City
Usti Nad Labem
ZIP/Postal Code
401 13
Country
Czech Republic
Facility Name
Local Institution
City
Usti Nad Orlici
ZIP/Postal Code
562 18
Country
Czech Republic
Facility Name
Local Institution
City
Arhus C
ZIP/Postal Code
8000
Country
Denmark
Facility Name
Local Institution
City
Hellerup
ZIP/Postal Code
2900
Country
Denmark
Facility Name
Local Institution
City
Herning
ZIP/Postal Code
7400
Country
Denmark
Facility Name
Local Institution
City
Hilleroed
ZIP/Postal Code
3400
Country
Denmark
Facility Name
Local Institution
City
Horsens
ZIP/Postal Code
8700
Country
Denmark
Facility Name
Local Institution
City
Naestved
ZIP/Postal Code
4700
Country
Denmark
Facility Name
Local Institution
City
Silkeborg
ZIP/Postal Code
8600
Country
Denmark
Facility Name
Local Institution
City
Angers
ZIP/Postal Code
49000
Country
France
Facility Name
Local Institution
City
Arras
ZIP/Postal Code
62022
Country
France
Facility Name
Local Institution
City
Besancon
ZIP/Postal Code
25000
Country
France
Facility Name
Local Institution
City
Clamart
ZIP/Postal Code
92141
Country
France
Facility Name
Local Institution
City
Clermont-Ferrand Cedex 01
ZIP/Postal Code
63003
Country
France
Facility Name
Local Institution
City
Dijon
ZIP/Postal Code
21079
Country
France
Facility Name
Local Institution
City
Grenoble Cedex 9
ZIP/Postal Code
38043
Country
France
Facility Name
Local Institution
City
Langres Cedex
ZIP/Postal Code
52206
Country
France
Facility Name
Local Institution
City
Le Kremlin-Bicetre
ZIP/Postal Code
94275
Country
France
Facility Name
Local Institution
City
Lille Cedex
ZIP/Postal Code
59020
Country
France
Facility Name
Local Institution
City
Limoges Cedex
ZIP/Postal Code
87042
Country
France
Facility Name
Local Institution
City
Nantes
ZIP/Postal Code
44093
Country
France
Facility Name
Local Institution
City
Paris
ZIP/Postal Code
75004
Country
France
Facility Name
Local Institution
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
Local Institution
City
Pierre Benite
ZIP/Postal Code
69495
Country
France
Facility Name
Local Institution
City
Saint-Priest En Jarez
ZIP/Postal Code
42270
Country
France
Facility Name
Local Institution
City
Toulouse cedex 9
ZIP/Postal Code
31059
Country
France
Facility Name
Local Institution
City
Vernon
ZIP/Postal Code
27200
Country
France
Facility Name
Local Institution
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Facility Name
Local Institution
City
Berlin
ZIP/Postal Code
10787
Country
Germany
Facility Name
Local Institution
City
Berlin
ZIP/Postal Code
12559
Country
Germany
Facility Name
Local Institution
City
Berlin
ZIP/Postal Code
14050
Country
Germany
Facility Name
Local Institution
City
Bochum
ZIP/Postal Code
44791
Country
Germany
Facility Name
Local Institution
City
Cologne
ZIP/Postal Code
50937
Country
Germany
Facility Name
Local Institution
City
Dortmund
ZIP/Postal Code
44137
Country
Germany
Facility Name
Local Institution
City
Dresden
ZIP/Postal Code
01067
Country
Germany
Facility Name
Local Institution
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Local Institution
City
Frankfurt
ZIP/Postal Code
60596
Country
Germany
Facility Name
Local Institution
City
Gottingen
ZIP/Postal Code
37075
Country
Germany
Facility Name
Local Institution
City
Karlsbad
ZIP/Postal Code
76307
Country
Germany
Facility Name
Local Institution
City
Ludwigshafen
ZIP/Postal Code
67063
Country
Germany
Facility Name
Local Institution
City
Mannheim
ZIP/Postal Code
68161
Country
Germany
Facility Name
Local Institution
City
Mannheim
ZIP/Postal Code
68163
Country
Germany
Facility Name
Local Institution
City
Munchen
ZIP/Postal Code
80331
Country
Germany
Facility Name
Local Institution
City
Munich
ZIP/Postal Code
80336
Country
Germany
Facility Name
Local Institution
City
Pokfulman
ZIP/Postal Code
XXXXX
Country
Hong Kong
Facility Name
Local Institution
City
Shatin, N.T
Country
Hong Kong
Facility Name
Local Institution
City
Budapest
ZIP/Postal Code
1032
Country
Hungary
Facility Name
Local Institution
City
Budapest
ZIP/Postal Code
1097
Country
Hungary
Facility Name
Local Institution
City
Budapest
ZIP/Postal Code
1125
Country
Hungary
Facility Name
Local Institution
City
Gyula
ZIP/Postal Code
5700
Country
Hungary
Facility Name
Local Institution
City
Kecskemet
ZIP/Postal Code
6000
Country
Hungary
Facility Name
Local Institution
City
Miskolc
ZIP/Postal Code
3501
Country
Hungary
Facility Name
Local Institution
City
Mosonmagyarovar
ZIP/Postal Code
9200
Country
Hungary
Facility Name
Local Institution
City
Szekesfehervar
ZIP/Postal Code
8000
Country
Hungary
Facility Name
Local Institution
City
Zalaegerszeg
ZIP/Postal Code
8900
Country
Hungary
Facility Name
Local Institution
City
Hyderabad
State/Province
Andhra Pradesh
ZIP/Postal Code
500 082
Country
India
Facility Name
Local Institution
City
Hyderabad
State/Province
Andhra Pradesh
ZIP/Postal Code
500034
Country
India
Facility Name
Local Institution
City
Ahmedabad
State/Province
Gujarat
ZIP/Postal Code
380006
Country
India
Facility Name
Local Institution
City
Gurgaon
State/Province
Haryana
ZIP/Postal Code
122001
Country
India
Facility Name
Local Institution
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560054
Country
India
Facility Name
Local Institution
City
Bengaluru
State/Province
Karnataka
ZIP/Postal Code
560017
Country
India
Facility Name
Local Institution
City
Manipal
State/Province
Karnataka
ZIP/Postal Code
576104
Country
India
Facility Name
Local Institution
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411001
Country
India
Facility Name
Local Institution
City
Mohali
State/Province
Punjab
ZIP/Postal Code
160062
Country
India
Facility Name
Local Institution
City
Ludhiana
State/Province
Tagore Nagar
ZIP/Postal Code
141001
Country
India
Facility Name
Local Institution
City
Chennai
State/Province
Tamil Nadu
ZIP/Postal Code
600 006
Country
India
Facility Name
Local Institution
City
Bangalore
ZIP/Postal Code
560052
Country
India
Facility Name
Local Institution
City
Bangalore
ZIP/Postal Code
560099
Country
India
Facility Name
Local Institution
City
Pune
ZIP/Postal Code
411001
Country
India
Facility Name
Local Institution
City
Tiberias
State/Province
Lower Galillee
ZIP/Postal Code
15208
Country
Israel
Facility Name
Local Institution
City
Afula
ZIP/Postal Code
18101
Country
Israel
Facility Name
Local Institution
City
Ashkelon
ZIP/Postal Code
78278
Country
Israel
Facility Name
Local Institution
City
Hadera
ZIP/Postal Code
38101
Country
Israel
Facility Name
Local Institution
City
Haifa
ZIP/Postal Code
31048
Country
Israel
Facility Name
Local Institution
City
Haifa
ZIP/Postal Code
31096
Country
Israel
Facility Name
Local Institution
City
Holon
ZIP/Postal Code
58100
Country
Israel
Facility Name
Local Institution
City
Jerusalem
ZIP/Postal Code
91031
Country
Israel
Facility Name
Local Institution
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Facility Name
Local Institution
City
Kfar Saba
ZIP/Postal Code
44281
Country
Israel
Facility Name
Local Institution
City
Nahariya
ZIP/Postal Code
22100
Country
Israel
Facility Name
Local Institution
City
Petach-Tikva
ZIP/Postal Code
49100
Country
Israel
Facility Name
Local Institution
City
Rehovot
ZIP/Postal Code
76100
Country
Israel
Facility Name
Local Institution
City
Safed
ZIP/Postal Code
13100
Country
Israel
Facility Name
Local Institution
City
Tel Aviv
ZIP/Postal Code
64239
Country
Israel
Facility Name
Local Institution
City
Tel Hashomer
ZIP/Postal Code
52621
Country
Israel
Facility Name
Local Institution
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Facility Name
Local Institution
City
Castelfranco Veneto (Tv)
ZIP/Postal Code
31033
Country
Italy
Facility Name
Local Institution
City
Chieti Scalo
ZIP/Postal Code
66013
Country
Italy
Facility Name
Local Institution
City
Cosenza
ZIP/Postal Code
87100
Country
Italy
Facility Name
Local Institution
City
Milano
ZIP/Postal Code
20132
Country
Italy
Facility Name
Local Institution
City
Padova
ZIP/Postal Code
35128
Country
Italy
Facility Name
Local Institution
City
Palermo
ZIP/Postal Code
90127
Country
Italy
Facility Name
Local Institution
City
Pavia
ZIP/Postal Code
27100
Country
Italy
Facility Name
Local Institution
City
Piacenza
ZIP/Postal Code
29100
Country
Italy
Facility Name
Local Institution
City
Pisa
ZIP/Postal Code
56124
Country
Italy
Facility Name
Local Institution
City
Reggio Emilia
ZIP/Postal Code
42100
Country
Italy
Facility Name
Local Institution
City
Rome
ZIP/Postal Code
00168
Country
Italy
Facility Name
Local Institution
City
Rozzano (Mi)
ZIP/Postal Code
20089
Country
Italy
Facility Name
Local Institution
City
San Daniele Del Friuli (Ud)
ZIP/Postal Code
33038
Country
Italy
Facility Name
Local Institution
City
Vicenza
ZIP/Postal Code
36100
Country
Italy
Facility Name
Local Institution
City
Vittorio Veneto (Tv)
ZIP/Postal Code
31029
Country
Italy
Facility Name
Local Institution
City
Busan
ZIP/Postal Code
602-702
Country
Korea, Republic of
Facility Name
Local Institution
City
Seoul
ZIP/Postal Code
120752
Country
Korea, Republic of
Facility Name
Local Institution
City
Seoul
ZIP/Postal Code
137-040
Country
Korea, Republic of
Facility Name
Local Institution
City
Seoul
ZIP/Postal Code
138736
Country
Korea, Republic of
Facility Name
Local Institution
City
Georgetown
State/Province
Penang
ZIP/Postal Code
10350
Country
Malaysia
Facility Name
Local Institution
City
Ipoh
State/Province
Perak
ZIP/Postal Code
30990
Country
Malaysia
Facility Name
Local Institution
City
Kuala Lumpur
ZIP/Postal Code
50586
Country
Malaysia
Facility Name
Local Institution
City
Melaka
ZIP/Postal Code
75400
Country
Malaysia
Facility Name
Local Institution
City
Tijuana
State/Province
Baja California
ZIP/Postal Code
22500
Country
Mexico
Facility Name
Local Institution
City
Leon
State/Province
Guanajuato
ZIP/Postal Code
37320
Country
Mexico
Facility Name
Local Institution
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44280
Country
Mexico
Facility Name
Local Institution
City
Zapopan
State/Province
Jalisco
ZIP/Postal Code
45170
Country
Mexico
Facility Name
Local Institution
City
Zapopan
State/Province
Jalisco
ZIP/Postal Code
45200
Country
Mexico
Facility Name
Local Institution
City
Monterrey
State/Province
Nuevo Leon
ZIP/Postal Code
64000
Country
Mexico
Facility Name
Local Institution
City
Monterrey
State/Province
Nuevo Leon
ZIP/Postal Code
64718
Country
Mexico
Facility Name
Local Institution
City
Xalapa
State/Province
Veracruz
ZIP/Postal Code
91020
Country
Mexico
Facility Name
Local Institution
City
Aguascalientes
ZIP/Postal Code
20230
Country
Mexico
Facility Name
Local Institution
City
Durango
ZIP/Postal Code
34080
Country
Mexico
Facility Name
Local Institution
City
Alesund
ZIP/Postal Code
6017
Country
Norway
Facility Name
Local Institution
City
Fredrikstad
ZIP/Postal Code
1606
Country
Norway
Facility Name
Local Institution
City
Gjettum
ZIP/Postal Code
1346
Country
Norway
Facility Name
Local Institution
City
Gjovik
ZIP/Postal Code
2819
Country
Norway
Facility Name
Local Institution
City
Hamar
ZIP/Postal Code
2318
Country
Norway
Facility Name
Local Institution
City
Oslo
ZIP/Postal Code
0319
Country
Norway
Facility Name
Local Institution
City
Oslo
ZIP/Postal Code
0407
Country
Norway
Facility Name
Local Institution
City
Oslo
ZIP/Postal Code
0456
Country
Norway
Facility Name
Local Institution
City
Trondheim
ZIP/Postal Code
7006
Country
Norway
Facility Name
Local Institution
City
Tynset
ZIP/Postal Code
2500
Country
Norway
Facility Name
Local Institution
City
Bialystok
ZIP/Postal Code
15-276
Country
Poland
Facility Name
Local Institution
City
Bydgoszcz
ZIP/Postal Code
85-168
Country
Poland
Facility Name
Local Institution
City
Bydgoszcz
ZIP/Postal Code
85-681
Country
Poland
Facility Name
Local Institution
City
Gdansk
ZIP/Postal Code
80-803
Country
Poland
Facility Name
Local Institution
City
Gdynia
ZIP/Postal Code
81-348
Country
Poland
Facility Name
Local Institution
City
Lodz
ZIP/Postal Code
90-153
Country
Poland
Facility Name
Local Institution
City
Lublin
ZIP/Postal Code
20-081
Country
Poland
Facility Name
Local Institution
City
Lublin
ZIP/Postal Code
20-718
Country
Poland
Facility Name
Local Institution
City
Poznan
ZIP/Postal Code
61-848
Country
Poland
Facility Name
Local Institution
City
Przeworsk
ZIP/Postal Code
37-200
Country
Poland
Facility Name
Local Institution
City
Szczecin
ZIP/Postal Code
70-111
Country
Poland
Facility Name
Local Institution
City
Warsawa
ZIP/Postal Code
02-776
Country
Poland
Facility Name
Local Institution
City
Warsaw
ZIP/Postal Code
02-005
Country
Poland
Facility Name
Local Institution
City
Warszawa
ZIP/Postal Code
01-138
Country
Poland
Facility Name
Local Institution
City
Wroclaw
ZIP/Postal Code
50-981
Country
Poland
Facility Name
Local Institution
City
Wroclaw
ZIP/Postal Code
51-124
Country
Poland
Facility Name
Local Institution
City
Coimbra
ZIP/Postal Code
3004-548
Country
Portugal
Facility Name
Local Institution
City
Guarda
ZIP/Postal Code
6301-857
Country
Portugal
Facility Name
Local Institution
City
Lisboa
ZIP/Postal Code
1169-050
Country
Portugal
Facility Name
Local Institution
City
Lisboa
ZIP/Postal Code
1769-001
Country
Portugal
Facility Name
Local Institution
City
San Juan
ZIP/Postal Code
00921
Country
Puerto Rico
Facility Name
Local Institution
City
Baia Mare
ZIP/Postal Code
430031
Country
Romania
Facility Name
Local Institution
City
Bucharest
ZIP/Postal Code
022328
Country
Romania
Facility Name
Local Institution
City
Bucharest
ZIP/Postal Code
030171
Country
Romania
Facility Name
Local Institution
City
Bucharest
ZIP/Postal Code
050098
Country
Romania
Facility Name
Local Institution
City
Targu Mures
ZIP/Postal Code
540136
Country
Romania
Facility Name
Local Institution
City
Arkhangelsk
ZIP/Postal Code
163045
Country
Russian Federation
Facility Name
Local Institution
City
Chelyabinsk
ZIP/Postal Code
454136
Country
Russian Federation
Facility Name
Local Institution
City
Kazan
ZIP/Postal Code
420101
Country
Russian Federation
Facility Name
Local Institution
City
Moscow
ZIP/Postal Code
109386
Country
Russian Federation
Facility Name
Local Institution
City
Moscow
ZIP/Postal Code
111539
Country
Russian Federation
Facility Name
Local Institution
City
Moscow
ZIP/Postal Code
115093
Country
Russian Federation
Facility Name
Local Institution
City
Moscow
ZIP/Postal Code
115280
Country
Russian Federation
Facility Name
Local Institution
City
Moscow
ZIP/Postal Code
117292
Country
Russian Federation
Facility Name
Local Institution
City
Moscow
ZIP/Postal Code
119049
Country
Russian Federation
Facility Name
Local Institution
City
Moscow
ZIP/Postal Code
121359
Country
Russian Federation
Facility Name
Local Institution
City
Moscow
ZIP/Postal Code
121552
Country
Russian Federation
Facility Name
Local Institution
City
Moscow
ZIP/Postal Code
127473
Country
Russian Federation
Facility Name
Local Institution
City
Novosibirsk
ZIP/Postal Code
630090
Country
Russian Federation
Facility Name
Local Institution
City
Rostov-On Don
ZIP/Postal Code
344022
Country
Russian Federation
Facility Name
Local Institution
City
Ryazan
ZIP/Postal Code
390026
Country
Russian Federation
Facility Name
Local Institution
City
Saint Petersburg
ZIP/Postal Code
192242
Country
Russian Federation
Facility Name
Local Institution
City
Saint Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
Facility Name
Local Institution
City
Saint-Petersburg
ZIP/Postal Code
196247
Country
Russian Federation
Facility Name
Local Institution
City
Saint-Petersburg
ZIP/Postal Code
197341
Country
Russian Federation
Facility Name
Local Institution
City
Saint-Petersburg
ZIP/Postal Code
199106
Country
Russian Federation
Facility Name
Local Institution
City
Saratov
ZIP/Postal Code
410012
Country
Russian Federation
Facility Name
Local Institution
City
St Petersburg
ZIP/Postal Code
194044
Country
Russian Federation
Facility Name
Local Institution
City
Yaroslavl
ZIP/Postal Code
150062
Country
Russian Federation
Facility Name
Local Institution
City
Singapore
ZIP/Postal Code
169608
Country
Singapore
Facility Name
Local Institution
City
Singapore
ZIP/Postal Code
308433
Country
Singapore
Facility Name
Local Institution
City
Singapore
ZIP/Postal Code
529889
Country
Singapore
Facility Name
Local Institution
City
Bioemfontein
State/Province
Free State
ZIP/Postal Code
9301
Country
South Africa
Facility Name
Local Institution
City
Centurion
State/Province
Gauteng
ZIP/Postal Code
0157
Country
South Africa
Facility Name
Local Institution
City
Parktown
State/Province
Gauteng
ZIP/Postal Code
2193
Country
South Africa
Facility Name
Local Institution
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0084
Country
South Africa
Facility Name
Local Institution
City
Durban
State/Province
Kwa Zulu Natal
ZIP/Postal Code
4001
Country
South Africa
Facility Name
Local Institution
City
Pietermaritzburg
State/Province
Kwa Zulu Natal
ZIP/Postal Code
3201
Country
South Africa
Facility Name
Local Institution
City
Bellville
State/Province
Western Cape
ZIP/Postal Code
7530
Country
South Africa
Facility Name
Local Institution
City
George
State/Province
Western Cape
ZIP/Postal Code
6529
Country
South Africa
Facility Name
Local Institution
City
Somerset West
State/Province
Western Cape
ZIP/Postal Code
7130
Country
South Africa
Facility Name
Local Institution
City
Worcester
State/Province
Western Cape
ZIP/Postal Code
6850
Country
South Africa
Facility Name
Local Institution
City
Torrevieja
State/Province
Alicante
ZIP/Postal Code
03186
Country
Spain
Facility Name
Local Institution
City
Getafe
ZIP/Postal Code
28905
Country
Spain
Facility Name
Local Institution
City
L'Hospitalet De Llobregat
ZIP/Postal Code
08907
Country
Spain
Facility Name
Local Institution
City
Leon
ZIP/Postal Code
24008
Country
Spain
Facility Name
Local Institution
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Local Institution
City
Madrid
ZIP/Postal Code
28029
Country
Spain
Facility Name
Local Institution
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Local Institution
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Local Institution
City
Mourente
ZIP/Postal Code
36071
Country
Spain
Facility Name
Local Institution
City
Tarragona
ZIP/Postal Code
43007
Country
Spain
Facility Name
Local Institution
City
Chernihiv
ZIP/Postal Code
14034
Country
Ukraine
Facility Name
Local Institution
City
Dnipropetrovsk
ZIP/Postal Code
49000
Country
Ukraine
Facility Name
Local Institution
City
Donetsk
ZIP/Postal Code
83045
Country
Ukraine
Facility Name
Local Institution
City
Ivano-Frankivsk
ZIP/Postal Code
76008
Country
Ukraine
Facility Name
Local Institution
City
Ivano-Frankivsk
ZIP/Postal Code
76018
Country
Ukraine
Facility Name
Local Institution
City
Kharkiv
ZIP/Postal Code
61018
Country
Ukraine
Facility Name
Local Institution
City
Kyiv
ZIP/Postal Code
03680
Country
Ukraine
Facility Name
Local Institution
City
Lviv
ZIP/Postal Code
79010
Country
Ukraine
Facility Name
Local Institution
City
Odesa
ZIP/Postal Code
65117
Country
Ukraine
Facility Name
Local Institution
City
Ternopil
ZIP/Postal Code
46000
Country
Ukraine
Facility Name
Local Institution
City
Vinnytsia
ZIP/Postal Code
21018
Country
Ukraine
Facility Name
Local Institution
City
Zaporizhzhia
ZIP/Postal Code
69035
Country
Ukraine
Facility Name
Local Institution
City
Livingston
State/Province
West Lothian
ZIP/Postal Code
EH54 7BH
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
35570249
Citation
Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16.
Results Reference
derived
PubMed Identifier
33890242
Citation
Cohen AT, Pan S, Byon W, Ilyas BS, Taylor T, Lee TC. Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY. Adv Ther. 2021 Jun;38(6):3003-3018. doi: 10.1007/s12325-021-01716-8. Epub 2021 Apr 22. Erratum In: Adv Ther. 2021 Aug;38(8):4596-4597.
Results Reference
derived
PubMed Identifier
30650446
Citation
Cohen AT, Agnelli G, Buller HR, Gallus A, Raskob GE, Sanders P, Thompson J, Weitz JI. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar;119(3):461-466. doi: 10.1055/s-0038-1676983. Epub 2019 Jan 16.
Results Reference
derived
PubMed Identifier
26627879
Citation
Liu X, Johnson M, Mardekian J, Phatak H, Thompson J, Cohen AT. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. J Am Heart Assoc. 2015 Dec 1;4(12):e002340. doi: 10.1161/JAHA.115.002340.
Results Reference
derived
PubMed Identifier
23808982
Citation
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.
Results Reference
derived
Links:
URL
http://www.bms.com/studyconnect/Pages/home.aspx
Description
BMS clinical trial educational resource
Learn more about this trial
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
We'll reach out to this number within 24 hrs